Generation of Autologous Antileukemia T-Cell Lines From the Bone Marrow of Patients With B-Cell Precursor ALL
| Patient . | Expression of CD40 . | T-Cell Expansion . | Leukemia Cytolysis (%) . | E/T Ratio . | CD8+ T Cells (%) . | TCRαβ+ T Cells (%) . | CD45RO+ T Cells (%) . |
|---|---|---|---|---|---|---|---|
| ALL-17 | 67% (29) | 44.7 | 45% | 20:1 | 73 | 100 | 83 |
| ALL-20 | 88% (41) | 51.4 | 37% | 40:1 | 76 | nd | nd |
| ALL-21 | 94% (53) | 42.4 | 63% | 40:1 | 69 | nd | nd |
| ALL-25 | 77% (31) | 14.5 | 51% | 20:1 | 62 | 99 | 95 |
| ALL-28 | 98% (323) | 49.5 | 48% | 40:1 | 67 | 100 | 87 |
| ALL-30 | 97% (69) | — | — | — | — | — | — |
| ALL-31 | 54% (27) | 10.4 | 28% | 20:1 | 59 | 97 | 91 |
| ALL-33 | 99% (80) | 21.3 | 55% | 30:1 | 75 | 100 | 94 |
| ALL-36 | 99% (75) | — | — | — | — | — | — |
| ALL-38 | 69% (17) | — | — | — | — | — | — |
| ALL-41 | 95% (37) | 31.6 | 32% | 30:1 | 82 | 98 | 72 |
| ALL-43 | 98% (87) | 27.1 | 25% | 40:1 | 77 | 100 | 80 |
| ALL-61 | 69% (39) | — | — | — | — | — | — |
| ALL-67 | 84% (20) | — | — | — | — | — | — |
| ALL-74 | 96% (68) | 19.2 | 42% | 40:1 | 71 | 100 | 86 |
| ALL-76 | ND | 25.4 | 29% | 40:1 | 75 | 100 | 79 |
| ALL-81 | ND | 29.6 | 47% | 40:1 | 70 | 100 | 87 |
| ALL-83 | 36% (4) | 48.2 | 39% | 40:1 | 84 | 100 | 77 |
| ALL-84 | 76% (48) | 36.3 | 30% | 40:1 | 78 | 98 | 89 |
| Patient . | Expression of CD40 . | T-Cell Expansion . | Leukemia Cytolysis (%) . | E/T Ratio . | CD8+ T Cells (%) . | TCRαβ+ T Cells (%) . | CD45RO+ T Cells (%) . |
|---|---|---|---|---|---|---|---|
| ALL-17 | 67% (29) | 44.7 | 45% | 20:1 | 73 | 100 | 83 |
| ALL-20 | 88% (41) | 51.4 | 37% | 40:1 | 76 | nd | nd |
| ALL-21 | 94% (53) | 42.4 | 63% | 40:1 | 69 | nd | nd |
| ALL-25 | 77% (31) | 14.5 | 51% | 20:1 | 62 | 99 | 95 |
| ALL-28 | 98% (323) | 49.5 | 48% | 40:1 | 67 | 100 | 87 |
| ALL-30 | 97% (69) | — | — | — | — | — | — |
| ALL-31 | 54% (27) | 10.4 | 28% | 20:1 | 59 | 97 | 91 |
| ALL-33 | 99% (80) | 21.3 | 55% | 30:1 | 75 | 100 | 94 |
| ALL-36 | 99% (75) | — | — | — | — | — | — |
| ALL-38 | 69% (17) | — | — | — | — | — | — |
| ALL-41 | 95% (37) | 31.6 | 32% | 30:1 | 82 | 98 | 72 |
| ALL-43 | 98% (87) | 27.1 | 25% | 40:1 | 77 | 100 | 80 |
| ALL-61 | 69% (39) | — | — | — | — | — | — |
| ALL-67 | 84% (20) | — | — | — | — | — | — |
| ALL-74 | 96% (68) | 19.2 | 42% | 40:1 | 71 | 100 | 86 |
| ALL-76 | ND | 25.4 | 29% | 40:1 | 75 | 100 | 79 |
| ALL-81 | ND | 29.6 | 47% | 40:1 | 70 | 100 | 87 |
| ALL-83 | 36% (4) | 48.2 | 39% | 40:1 | 84 | 100 | 77 |
| ALL-84 | 76% (48) | 36.3 | 30% | 40:1 | 78 | 98 | 89 |
Expression of CD40 represents the percentage (%) and mean intensity of fluorescence (MIF) at day 0 of the experiment. NDmeans that CD40 expression was not determined for these patients, but the leukemia cells responded to CD40L by induction/upregulation of B7-1 and B7-2.
Abbreviations: E/T, effector/target ratio; nd, not determined.